Recombinant humanized antibody expressed in CHO binding to human LOXL2. Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator.
Figure 1 Effects of Simtuzumab on normal myofibroblast differentiation and invasion.
Fibroblast cultures derived from normal lung samples were treated with anti-LOXL2 (1, 10, and 50 μg/ml), BIBF1120 (300 nM) and their respective controls in the absence or presence of CpG (10 nM), IL-13 (10 ng/ml) or TGF-β (20 ng/ml).
Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis. bioRxiv, 813907.
Figure 2 Effects of Simtuzumab on IPF myofibroblast differentiation and invasion.
Fibroblast cultures derived from IPF lung samples were treated with anti-LOXL2 (1, 10, and 50 μg/ml), BIBF1120 (300 nM) and their respective controls in the absence or presence of CpG (10 nM), IL-13 (10 ng/ml) or TGF-β (20 ng/ml).
Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis. bioRxiv, 813907.
Figure 3 Simtuzumab accelerates cell differentiation in vitro.
Explanted lung cells from normal and IPF lung samples were treated with anti-LOXL2 (50 μg/ml), or IgG for 26 days. Media and treatments were replaced 2x/week until day 26.
Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis. bioRxiv, 813907.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-LOXL2 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-890)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human LOXL2. It is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator.
DrugMonitor™ Anti-Simtuzumab Antibody (VS-1224-YC1091)Simtuzumab has been explored in trials for the treatment of myelofibrosis, pancreatic cancer, colorectal cancer, and idiopathic pulmonary fibrosis. The DrugMonitor™ Anti-Simtuzumab Antibody (VS-1224-YC1091) is an anti-drug antibody (ADA) against Simtuzumab. This drug-based antibody is raised in mice immunized with the Simtuzumab. The anti-Simtuzumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Simtuzumab in samples.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0693CL | Mouse Anti-LOXL2 Recombinant Antibody (TAB-0693CL) | IF, ELISA, FC | Mouse IgG |
TAB-0693CL-S(P) | Mouse Anti-LOXL2 Recombinant Antibody; scFv Fragment (TAB-0693CL-S(P)) | ELISA, FC | Mouse scFv |
TAB-0693CL-F(E) | Mouse Anti-LOXL2 Recombinant Antibody; Fab Fragment (TAB-0693CL-F(E)) | ELISA, FC | Mouse Fab |
There are currently no Customer reviews or questions for TAB-890. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-890, RRID: AB_3112015)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.